Shares of Cambrex Corp. (NYSE:CBM) hit a new 52-week high during mid-day trading on Wednesday . The company traded as high as $59.19 and last traded at $58.96, with a volume of 126,981 shares. The stock had previously closed at $57.88.

Separately, Zacks Investment Research upgraded Cambrex Corp. from a “hold” rating to a “strong-buy” rating and set a $56.00 price target for the company in a report on Wednesday, May 4th.

The company has a market capitalization of $1.88 billion and a PE ratio of 30.15. The firm has a 50-day moving average price of $52.41 and a 200-day moving average price of $44.91.

Cambrex Corp. (NYSE:CBM) last announced its quarterly earnings data on Friday, April 29th. The company reported $0.50 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.34 by $0.16. During the same period in the prior year, the company posted $0.29 earnings per share. The business earned $94.74 million during the quarter, compared to analysts’ expectations of $83.61 million. The firm’s revenue was up 22.2% on a year-over-year basis. On average, equities analysts forecast that Cambrex Corp. will post $2.56 earnings per share for the current year.

In related news, Director William B. Korb sold 3,420 shares of the stock in a transaction dated Monday, July 11th. The stock was sold at an average price of $55.00, for a total value of $188,100.00. Following the completion of the sale, the director now directly owns 23,982 shares of the company’s stock, valued at approximately $1,319,010. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director William B. Korb sold 8,000 shares of the stock in a transaction dated Tuesday, May 3rd. The stock was sold at an average price of $49.09, for a total value of $392,720.00. Following the completion of the sale, the director now directly owns 32,562 shares of the company’s stock, valued at $1,598,468.58. The disclosure for this sale can be found here.

A number of large investors have made changes to their positions in the company. Victory Capital Management Inc. increased its stake in shares of Cambrex Corp. by 13,241.1% in the fourth quarter. Victory Capital Management Inc. now owns 142,483 shares of the company’s stock valued at $6,710,000 after buying an additional 141,415 shares in the last quarter. Morgan Stanley increased its stake in shares of Cambrex Corp. by 27.9% in the fourth quarter. Morgan Stanley now owns 323,861 shares of the company’s stock valued at $15,250,000 after buying an additional 70,585 shares in the last quarter. Dimensional Fund Advisors LP increased its stake in shares of Cambrex Corp. by 3.1% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,589,449 shares of the company’s stock valued at $74,848,000 after buying an additional 47,279 shares in the last quarter. Turner Investments L.P. acquired a new stake in shares of Cambrex Corp. during the fourth quarter valued at about $2,119,000. Finally, Century Capital Management LLC increased its stake in shares of Cambrex Corp. by 13.5% in the fourth quarter. Century Capital Management LLC now owns 353,591 shares of the company’s stock valued at $16,651,000 after buying an additional 42,189 shares in the last quarter.

Cambrex Corporation (Cambrex) is a life sciences company. The Company provides products and services for the development and commercialization of new and generic therapeutics. The Company supplies its products and services across the world to generic pharmaceutical companies. Cambrex operates through three segments, which are manufacturing facilities.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.